RNA Sequencing Reveals Differentially Expressed Genes in Left Ventricular Biopsies from Ischemic and Dilated Cardiomyopathy Patients
Heart failure (HF) affects more than 6 million adults in the U.S and is associated with significant morbidity and mortality. The majority of HF patients suffer from either ischemic (ICM) or dilated (DCM) cardiomyopathy. Little is known about the genetic alterations in DCM or ICM patients. Therefore, our aim was to characterize differentially expressed genes in left ventricular tissue from DCM and ICM patients.
Patients with dilated cardiomyopathy (DCM) who achieved left ventricular reverse remodeling (LVRR) have a favorable prognosis, but it is still difficult to precisely predict LVRR in the clinical setting.
Myocarditis is a known etiology of both acute fulminant heart failure and chronic dilated cardiomyopathy requiring heart transplantation. We sought to evaluate the long-term post-transplant outcomes of pts with myocarditis.
We aim to evaluate clinical outcomes, echocardiographic changes, heart rate (HR) modifications and side effects in children with dilated cardiomyopathy (DCM) and chronic heart failure (HF) treated by high dosage of carvedilol.
Dilated cardiomyopathy (DCM) is a common cause of advanced heart failure (HF) in children and the risk of sudden death in DCM is not well defined although population-based studies have described risk factors like older age, familial DCM and lower fractional shortening. Myocardial fibrosis as assessed by late gadolinium enhancement (LGE) on 3-T cardiac magnetic resonance imaging (CMR) is well known to be associated with adverse events in DCM. We sought to assess the conditional survival (CS) of children and adolescents with DCM and advanced HF based on native T1 mapping (combined proton signal from myocytes and interstitium...
This study enrolled an institutional consecutive surgical series of 24 patients with refractory congestive heart failure under peripheral ECLS, related to fulminant myocarditis (n = 15), dilated cardiomyopathy (n = 5), or acute myocardial infarction (n = 4). They were converted to central Y-extracorporeal membrane oxygenation (ECMO,n = 6), extracorporeal ventricular assist device (EC-VAD,n = 12), or pump catheter (n = 6), dependent upon the degree of multiorgan failure. Despite the different degree of multiorgan failure prior to the convers...
This study demonstrates for the first time that senescent cells secrete functional LTs, significantly contributing to the LTs pool known to cause or exacerbate idiopathic pulmonary fibrosis. Against Senolytics https://www.fightaging.org/archives/2019/11/against-senolytics/ There is no consensus in science that is so strong as to have no heretics. So here we have an interview with a naysayer on the matter of senolytic treatments, who argues that the loss of senescent cells in aged tissues will cause more harm to long-term health than the damage they will do by remaining. To be clear, I think this to be a ...
CONCLUSIONS: These results demonstrate that patients with LMNA-related cardiomyopathy are characterized by VTs refractory to RFCA probably because of the deep intramural focus at the basal ventricular septum, resulting in poor prognosis with progressive severe heart failure despite all available optimized therapies. Thus, we should consider heart transplantation in their early 50s when several VT events begin to occur. PMID: 31060954 [PubMed - as supplied by publisher]
Occasionally new onset cardiomyopathy patients (pts) present late, in such advanced disease stage that they cannot tolerate heart failure (HF) drug therapy. We investigated the cardiac recovery (CR) potential following a combination of left ventricular assist device (LVAD) and guideline-directed HF drug therapy in this medication-naive population.
In this study, we tested the hypothesis that children and adults with DCM and heart failure (DCM/HF) display different plasma peptide biomarker profiles.
Pediatric heart transplantation is considered to be a standard therapy for end-stage heart failure refractory to medical and surgical therapy.1 Since its inception in 1967, heart transplant use has continually increased with expansion to more complex populations.2,3 A recent International Society of Heart and Lung Transplantation report evaluated post-transplantation outcomes among different transplant indications and found that despite ongoing improvement in overall pediatric transplant survival, there remains a persistent survival advantage for dilated cardiomyopathy compared to congenital heart disease (CHD) and retransplantation.